spleen
lymph
node
along
reduc
lymphocyt
lymphoid
organ
major
infiltr
immun
cell
lung
lesion
monocyt
macrophag
minim
lymphocyt
infiltr
mimicri
vascul
hypercoagul
multipl
organ
damag
base
characterist
discuss
follow
point
term
treatment
cytokin
storm
cs
refer
excess
uncontrol
releas
proinflammatori
cytokin
cytokin
storm
syndrom
caus
varieti
diseas
includ
infecti
diseas
rheumat
diseas
tumor
immunotherapi
clinic
commonli
present
system
inflamm
multipl
organ
failur
high
inflammatori
paramet
infecti
diseas
cs
usual
origin
focal
infect
area
spread
bodi
circul
coronaviru
pneumonia
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
accompani
rapid
viru
replic
larg
number
inflammatori
cell
infiltr
cs
led
acut
lung
injuri
acut
respiratori
distress
syndrom
ard
death
accumul
evid
reveal
part
sever
patient
elev
cytokin
profil
resembl
cs
sar
mer
huang
et
al
report
level
inflammatori
factor
patient
measur
cytokin
level
inpati
includ
icu
patient
non
icu
patient
fibroblast
growth
factor
fgf
granulocytemacrophag
coloni
stimul
factor
gmcsf
granulocytecoloni
stimul
factor
gcsf
protein
monocyt
chemoattract
protein
macrophag
inflammatori
protein
alpha
platelet
deriv
growth
factor
pdgf
tumor
necrosi
factor
vascular
endotheli
growth
factor
vegf
increas
among
gcsf
higher
sever
patient
notabl
pronounc
differ
serum
level
icu
non
icu
patient
howev
anoth
retrospect
multicentr
cohort
studi
studi
group
report
significantli
elev
level
nonsurviv
group
patient
compar
surviv
sever
report
also
confirm
elev
critic
ill
patient
sever
although
patient
lymphcytopenia
lymphocyt
activ
one
studi
analyz
lymphocyt
subset
cytokin
patient
patient
lymphcytopenia
percentag
cell
reduct
mild
sever
group
respect
nk
cell
reduct
mild
sever
group
also
serum
level
sever
group
significantli
higher
mild
group
addit
express
hladr
cell
increas
cell
also
increas
cytotox
particl
perforin
granolysin
highli
express
cell
consist
other
sever
patient
icu
ward
persist
high
level
erythematosu
sediment
rate
esr
crp
high
level
etc
associ
ard
hypercoagul
dissemin
intravascular
coagul
dic
manifest
thrombosi
thrombocytopenia
gangren
extrem
possibl
cs
exacerb
lung
damag
well
lead
fetal
complic
siddiqu
mehra
propos
classif
model
recogn
ill
exhibit
three
grade
increas
sever
correspond
distinct
clinic
find
respons
therapi
clinic
outcom
small
proport
patient
would
transit
third
sever
stage
ill
manifest
extrapulmonari
system
hyperinflamm
syndrom
stage
marker
system
inflamm
appear
extrem
elev
therefor
block
cs
initi
antiinflamm
therapi
critic
reduc
death
rate
lymphocytopenia
one
promin
marker
also
one
diagnost
criteria
china
cell
nk
cell
patient
reduc
degre
reduct
even
lower
sever
case
latter
higher
leukocyt
count
neutrophillymphocyteratio
nlr
well
critic
ill
patient
nk
cell
extrem
low
even
undetect
addit
memori
helper
cell
regulatori
cell
obvious
decreas
sever
case
strikingli
autopsi
find
reveal
secondari
lymphoid
tissu
destroy
patient
unusu
cs
relat
diseas
spleen
atrophi
observ
report
case
decreas
number
lymphocyt
signific
cell
degener
focal
hemorrhag
necrosi
macrophag
prolifer
macrophag
phagocytosi
found
spleen
similarli
lymph
node
atrophi
number
lymph
node
decreas
accompani
necrosi
immunohistochem
stain
show
cell
cell
decreas
spleen
lymph
node
addit
lung
characterist
diffus
alveolar
damag
dad
major
infiltr
cell
monocyt
macrophag
moder
multinucl
giant
cell
lymphocyt
infiltr
lymphocyt
cell
importantli
viru
inclus
bodi
still
detect
type
ii
alveolar
epithelia
macrophag
despit
pcr
test
neg
blood
throat
swab
find
consist
characterist
call
primari
cytokin
storm
induc
viral
infect
mainli
produc
alveolar
macrophag
epitheli
cell
endotheli
cell
rather
observ
secondari
cytokin
storm
induc
differ
subset
activ
lymphocyt
late
stage
viral
infect
complic
cellengag
therapi
two
possibl
reason
destruct
immun
system
patient
lymphocyt
directli
invad
viru
indirectli
damag
cs
know
infect
target
cell
angiotensin
convert
enzym
express
lymphocyt
specul
lymphocyt
probabl
destroy
cs
anoth
promin
clinic
manifest
sever
patient
endothelium
damag
mimicri
vascul
could
seen
sever
patient
clinic
mani
critic
ill
patient
vasculitislik
manifest
even
gangren
extrem
patholog
examin
reveal
blood
vessel
alveolar
septum
congest
edemat
modest
infiltr
monocyt
lymphocyt
within
around
blood
vessel
small
vessel
show
hyperplasia
vessel
wall
thicken
lumen
stenosi
occlus
focal
hemorrhag
hyalin
thrombi
microvessel
found
proport
sever
case
intriguingli
patient
test
posit
high
titer
antiphospholipid
antibodi
includ
anticardiolipin
antibodi
glycoprotein
antibodi
associ
sever
thrombosi
unpublish
data
underli
mechan
vascular
damag
may
due
direct
injuri
endotheli
cell
viru
lead
dic
antiphospholipid
syndrom
ap
mimicri
vascul
patholog
autoimmun
respons
involv
antiviru
immun
worth
emphas
doubt
antivir
support
treatment
import
treatment
patient
cs
rel
common
sever
case
often
lead
exacerb
antiinflamm
therapi
may
help
prevent
injuri
know
varieti
antiinflammatori
medic
includ
non
steroid
antiinflammatori
drug
glucocorticoid
chloroquinehydroxychloroquin
immunosuppress
inflammatori
cytokin
antagonist
monoclon
antibodi
tnf
inhibitor
antagonist
janu
kinas
inhibitor
jak
inhibitor
et
al
siddiqu
mehra
suggest
tailor
therapi
stage
iii
hing
use
immunomodulatori
agent
reduc
system
inflamm
overwhelmingli
result
multiorgan
dysfunct
phase
use
corticosteroid
may
justifi
concert
use
cytokin
inhibitor
tocilizumab
inhibitor
anakinra
receptor
antagonist
intraven
immun
globulin
ivig
may
also
play
role
modul
immun
system
hyperinflammatori
state
overal
prognosi
recoveri
critic
stage
ill
poor
prompt
recognit
applic
therapi
may
greatest
yield
howev
dilemma
antiinflammatori
therapi
balanc
risk
benefit
ratio
critic
issu
appli
antiinflamm
therapi
patient
patient
treat
antiinflamm
regimen
start
treatment
durat
medic
best
choic
question
still
intens
debat
reach
consensu
main
concern
antiinflammatori
medic
corticosteroid
may
delay
elimin
viru
increas
risk
secondari
infect
especi
impair
immun
system
secondli
biolog
agent
target
proinflammatori
cytokin
inhibit
specif
inflammatori
factor
thu
may
effect
curb
cs
cytokin
mayb
signific
import
thirdli
antiinflamm
medic
jak
inhibitor
also
block
infa
product
import
fight
viru
theoret
may
suitabl
treatment
inflammatori
cs
caus
viru
final
time
window
antiinflammatori
treatment
import
accord
report
observ
sever
patient
usual
underw
abrupt
deterior
week
onset
prompt
initi
antiinflammatori
therapi
extrem
short
time
window
like
achiev
favor
treatment
respons
numer
clinic
studi
report
efficaci
glucocorticoid
treatment
coronaviru
pneumonia
sar
mer
influenza
pneumonia
consensu
reach
sar
epidem
glucocorticoid
main
medic
immunomodulatori
therapi
time
usag
glucocorticoid
could
improv
earli
fever
promot
absorpt
pneumonia
obtain
better
oxygen
howev
studi
nt
show
benefici
effect
glucocorticoid
even
advers
reaction
delay
viru
clearanc
lead
deterior
diseas
accord
intern
guidelin
manag
sepsi
septic
shock
glucocorticoid
use
small
dosag
shortterm
applic
appli
patient
adequ
fluid
vasopressor
therapi
restor
hemodynam
stabil
present
system
glucocorticoid
administr
empir
use
sever
complic
order
suppress
cs
manifest
patient
ard
acut
heart
injuri
acut
kidney
complic
patient
higher
ddimer
level
et
al
howev
evid
random
clinic
trial
support
glucocorticoid
treatment
chen
et
al
report
patient
treat
glucocorticoid
day
median
methylprednisolon
mgkg
per
day
recommend
patient
ard
short
durat
treatment
possibl
howev
evid
indic
benefit
use
glucocorticoid
like
outweigh
advers
effect
wang
et
al
report
patient
given
glucocorticoid
therapi
effect
outcom
observ
russel
et
al
report
clinic
evid
support
corticosteroid
treatment
lung
injuri
due
lack
evid
interim
guidelin
support
use
system
corticosteroid
treatment
viral
pneumonia
ard
suspect
case
februari
therefor
efficaci
associ
advers
effect
glucocorticoid
need
elucid
tocilizumab
tcz
recombin
human
monoclon
antibodi
specif
bind
solubl
membranebound
receptor
thu
block
signal
mediat
inflammatori
respons
tcz
wide
use
rheumat
diseas
rheumatoid
arthriti
august
tcz
approv
unit
state
sever
lifethreaten
cytokin
releas
syndrom
caus
chimer
antigen
receptor
tcell
cart
immunotherapi
wei
haim
et
al
conduct
retrospect
studi
observ
efficaci
tocilizumab
treat
sever
critic
patient
publish
along
basic
antiviru
treatment
tcz
appli
patient
mg
intraven
within
day
fever
return
normal
symptom
improv
remark
improv
oxygen
opac
lung
lesion
ct
scan
absorb
patient
addit
percentag
peripher
lymphocyt
return
normal
patient
data
suggest
tcz
might
effect
treatment
sever
patient
till
sever
clinic
trial
regist
safeti
efficaci
tocilizumab
treatment
sever
pneumonia
adult
inpati
includ
multicent
random
control
trial
efficaci
safeti
tocilizumab
treatment
novel
coronari
pneumonia
ncp
singl
arm
open
multicent
studi
tocilizumab
combin
tocilizumab
drug
receptor
novel
coronaviru
pneumonia
might
cellsurfac
protein
wide
exist
cell
heart
kidney
blood
vessel
especi
alveolar
epitheli
cell
could
invad
enter
cell
endocytosi
one
known
regul
endocytosi
protein
kinas
inhibitor
interrupt
passag
viru
cell
help
prevent
viru
infect
baricitinib
jak
inhibitor
well
inhibitor
suggest
possibl
candid
treatment
consid
rel
safeti
high
affin
therapeut
dosag
either
mg
mg
daili
suffici
reach
plasma
concentr
inhibit
howev
mention
biggest
concern
jak
inhibitor
inhibit
varieti
inflammatori
cytokin
includ
infa
play
import
role
curb
viru
activ
clinic
trial
detail
analysi
warrant
confirm
efficaci
date
regist
clinic
trial
jak
inhibitor
studi
safeti
efficaci
jakotinib
hydrochlorid
tablet
treatment
sever
acut
exacerb
patient
novel
coronaviru
pneumonia
sever
novel
coronaviru
pneumonia
patient
treat
ruxolitinib
combin
mesenchym
stem
cell
prospect
singl
blind
random
control
clinic
trial
chloroquin
cq
amin
acidotrop
form
quinin
hydroxychloroquin
hcq
differ
chloroquin
presenc
hydroxyl
group
end
side
chain
nethyl
substitu
decad
cq
hcq
frontlin
medic
treatment
prophylaxi
malaria
also
use
treat
autoimmun
diseas
includ
rheumatoid
arthriti
ra
system
lupu
erythematosu
sle
previou
studi
report
cqhcq
possess
broad
spectrum
antivir
effect
varieti
virus
divers
human
immunodefici
viru
hiv
marburg
viru
zika
viru
dengu
viru
ebola
viru
etc
cq
hcq
interfer
bind
viral
particl
cellular
cell
surfac
receptor
phdepend
endosomemedi
viral
entri
envelop
virus
inhibit
viral
cycl
also
interfer
posttransl
modif
viral
protein
impair
proper
matur
viral
protein
ph
modul
addit
cq
hcq
regul
immun
system
affect
cell
signal
product
proinflammatori
cytokin
although
cq
hcq
frequent
use
treatment
rheumat
diseas
due
immunomodulatori
antiinflammatori
effect
benefit
treat
may
mainli
attribut
antivir
effect
recent
cq
hcq
shown
sever
studi
reduc
viral
load
shorten
durat
viremia
whether
immunomodulatori
effect
also
play
role
treatment
still
requir
investig
coronavirus
potenti
therapeut
benefit
cq
notabl
report
vitro
cq
prevent
infect
glycosyl
viru
cell
surfac
receptor
recent
public
result
show
cq
highli
effect
control
infect
vitro
till
clinic
trial
conduct
china
test
efficaci
safeti
cq
hcq
treatment
cq
hcq
anoth
includ
cq
hcq
far
clinic
trial
involv
patient
chloroquin
phosphat
group
show
efficaci
reduc
exacerb
pneumonia
improv
lung
imag
find
increas
neg
rate
viru
nucleic
acid
test
given
find
guidelin
version
treatment
recommend
chloroquin
phosphat
oral
administ
dose
mg
mg
chloroquin
adult
time
day
day
hydroxychloroquin
therapeut
effect
new
coronaviru
regist
februari
patient
enrol
hcq
basic
treatment
group
day
hcq
treatment
clinic
symptom
patient
improv
day
hcq
treatment
patient
improv
lung
imag
find
addit
none
mild
patient
exacerb
diseas
hcq
group
regard
safeti
two
advers
reaction
mild
rash
slight
headach
advers
reaction
disappear
adjust
regimen
result
clinic
trial
confirm
shortterm
efficaci
hcq
treatment
effect
improv
lung
imag
find
promot
virusneg
convers
shorten
diseas
cours
although
number
case
hcq
group
rel
small
current
data
provid
insight
clinician
efficaci
safeti
hcq
treatment
need
confirm
preclin
clinic
trial
conclus
viral
infecti
diseas
mainli
manifest
fever
pneumonia
antivir
respiratori
support
therapi
mainstream
treatment
sever
case
cs
occur
critic
patient
lead
ard
multipl
organ
damag
even
death
antiinflamm
treatment
may
appli
howev
given
viral
natur
cs
consid
substanti
impair
host
immun
system
sever
case
critic
balanc
risk
benefit
ratio
start
antiinflamm
therapi
addit
time
antiinflamm
treatment
initi
right
window
time
pivot
import
tailor
individu
patient
achiev
favor
effect
none
